wegovy glp-1 for the Treatment of Chronic Weight Management, US POTD: Wegovy and Ozempic —

sarcopenia), resistance training protocols (type, intensity, and duration), diet, and sample size limitations

It is also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (Ozempic), and in adults with established cardiovascular disease and either obesity or overweight (Wegovy)

The GLP-1 receptor is a type of cell surface receptor that binds to GLP-1, triggering a signaling cascade that leads to various effects, including the stimulation of insulin secretion, the inhibition of gastric emptying, and the promotion of satiety

We also summarized ongoing clinical trials evaluating MSTN inhibitors alone or in combination with GLP-1 agonists (Table 1)

[DOI] [PubMed] [Google Scholar] 167.Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M

After GLP-1 binding, G protein conjugates GLP-1R receptors to activate adenylate cyclase (AC) and increase intracellular cAMP levels